New vaccine strategy aims to shield lymphoma patients from deadly infections
NCT ID NCT04214444
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a two-step vaccine approach to prevent pneumococcal infections in 26 adults with diffuse large B-cell lymphoma who were receiving chemotherapy with rituximab. The vaccines, Prevenar and Pneumovax, were given in a prime-boost sequence to boost immune protection. The goal was to see if this strategy could improve antibody responses and reduce infection risk in these vulnerable patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GYAN
Tours, 37044, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study tracks pneumococcal infections in adults to sharpen vaccine strategies
- Text message nudge could save thousands from pneumonia
- Vaccine Follow-Up: how long does protection last in babies?
- New PET scan targets hidden cancers with precision
- French study tracks pneumococcal infections in kids after vaccine rollout
- Are hidden immune defects causing your recurring infections? new study investigates.